149 filings
8-K
MIST
Milestone Pharmaceuticals Inc.
4 Sep 24
Milestone Pharmaceuticals Appoints Industry Veteran Joseph Papa to its Board of Directors
8:07am
8-K
MIST
Milestone Pharmaceuticals Inc.
8 Aug 24
Milestone Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Regulatory and Corporate Update
4:28pm
ARS
2023 FY
MIST
Milestone Pharmaceuticals Inc.
15 Jul 24
Annual report to shareholders
4:41pm
DEFA14A
MIST
Milestone Pharmaceuticals Inc.
15 Jul 24
Additional proxy soliciting materials
4:38pm
DEFA14A
n78n2 yq1d1aso9jwh0
15 Jul 24
Additional proxy soliciting materials
4:36pm
8-K
xswc4u9 zovk3zobuj4c
15 Jul 24
Entry into a Material Definitive Agreement
4:02pm
8-K
bvnyh7nfc7
29 May 24
Other Events
7:09am
8-K
kjcfdkl6uc58
13 May 24
Milestone Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Regulatory and Corporate Update
7:34am
8-K
fixj2cygf lz
8 Apr 24
Data from this large safety-trial also published in The Journal of the American College of Cardiology
4:38pm
8-K
l99bvyw fk
28 Mar 24
Milestone Pharmaceuticals Announces Resubmission of New Drug Application for Etripamil for Treatment in Paroxysmal Supraventricular Tachycardia
7:07am
8-K
30zyx5vxttct
21 Mar 24
Milestone Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Regulatory and Corporate Update
7:21am
8-K
i28rvg
4 Mar 24
Milestone Pharmaceuticals Announces Proposed Public Offering of Common Shares and Pre-Funded Warrants
9:00am
424B5
i7lvm37qof
1 Mar 24
Prospectus supplement for primary offering
4:52pm
424B5
tow8po
28 Feb 24
Prospectus supplement for primary offering
5:21pm
8-K
6q94gn ldpyobt0b1if7
26 Feb 24
Milestone Pharmaceuticals Announces Plan to Resubmit NDA for Etripamil for the Treatment of PSVT
7:06am